TrialSignal transduction and targeted therapy2023

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.

Wen-Zhao Zhong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.